UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial

Journal of the American Academy of Dermatology, 2019-04, Vol.80 (4), p.1013-1021

2019

Volltextzugriff (PDF)

Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses

The New England journal of medicine, 2014-05, Vol.370 (22), p.2102-2110

2014

Volltextzugriff (PDF)

Baseline type 2 biomarker levels and response to tezepelumab in severe asthma

Allergy (Copenhagen), 2022-06, Vol.77 (6), p.1786-1796

2022

Volltextzugriff (PDF)

CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma

Respiratory research, 2020-10, Vol.21 (1), p.265-9, Article 265

2020

Volltextzugriff (PDF)

Tezepelumab in Adults with Uncontrolled Asthma

The New England journal of medicine, 2017-09, Vol.377 (10), p.936-946

2017

Volltextzugriff (PDF)

Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial

The lancet respiratory medicine, 2021-11, Vol.9 (11), p.1299-1312

2021

Volltextzugriff (PDF)

Immune Complex Formation Is Associated With Loss of Tolerance and an Antibody Response to Both Drug and Target

Frontiers in immunology, 2021-12, Vol.12, p.782788-782788

2021

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Tolerability of Tezepelumab (AMG 157) in Healthy and Atopic Dermatitis Adult Subjects

Clinical pharmacology and therapeutics, 2019-08, Vol.106 (2), p.441-449

2019

Volltextzugriff (PDF)

Safety and Biological Activity of Rozibafusp alfa, a Bispecific Inhibitor of Inducible Costimulator Ligand and B Cell Activating Factor, in Patients With Rheumatoid Arthritis: Results of a Phase 1b, Randomized, Double‐Blind, Placebo‐Controlled, Multiple Ascending Dose Study

ACR open rheumatology, 2022-10, Vol.4 (10), p.903-911

2022

Volltextzugriff (PDF)

Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials

American journal of respiratory and critical care medicine, 2023-07, Vol.208 (1), p.13-24

2023

Volltextzugriff (PDF)

Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY

Annals of allergy, asthma, & immunology, 2021-02, Vol.126 (2), p.187-193

2021

Volltextzugriff (PDF)

Targeting TSLP in Asthma

Journal of asthma and allergy, 2022-06, Vol.15, p.749-765

2022

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Properties of Rozibafusp Alfa, a Bispecific Inhibitor of BAFF and ICOSL: Analyses of Phase I Clinical Trials

Clinical pharmacology and therapeutics, 2023-08, Vol.114 (2), p.371-380

2023

Volltextzugriff (PDF)

Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma

Journal of clinical pharmacology, 2021-07, Vol.61 (7), p.901-912

2021

Volltextzugriff (PDF)

Tezepelumab normalizes serum interleukin-5 and -13 levels in patients with severe, uncontrolled asthma

Annals of allergy, asthma, & immunology, 2021-12, Vol.127 (6), p.689-691

2021

Volltextzugriff (PDF)

Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A Post Hoc Analysis of the Phase 2b PATHWAY Study

Journal of asthma and allergy, 2021-01, Vol.14, p.91-99

2021

Volltextzugriff (PDF)

Reply to Lipworth and Chan

American journal of respiratory and critical care medicine, 2023-07, Vol.208 (2), p.212-213

2023

Volltextzugriff (PDF)

Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy

The journal of allergy and clinical immunology in practice (Cambridge, MA), 2021-12, Vol.9 (12), p.4334-4342.e6

2021

Volltextzugriff (PDF)

Requirement for CD100–CD72 interactions in fine-tuning of B-cell antigen receptor signaling and homeostatic maintenance of the B-cell compartment

International immunology, 2005-10, Vol.17 (10), p.1277-1282

2005

Volltextzugriff (PDF)

Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study

Journal of asthma and allergy, 2021-01, Vol.14, p.1-11

2021

Volltextzugriff (PDF)

Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study

The lancet. Gastroenterology & hepatology, 2019-12, Vol.4 (12), p.948-959

2019

Volltextzugriff (PDF)

A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings

Nature metabolism, 2024-02, Vol.6 (2), p.290-303

2024

Volltextzugriff (PDF)

CD72 Down-Modulates BCR-Induced Signal Transduction and Diminishes Survival in Primary Mature B Lymphocytes

Journal of Immunology, 2006-05, Vol.176 (9), p.5321-5328

2006

Volltextzugriff (PDF)

Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study

The lancet. Gastroenterology & hepatology, 2019-12, Vol.4 (12), p.960-970

2019

Volltextzugriff (PDF)

Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells

Blood, 2006-04, Vol.107 (8), p.3212-3220

2006

Volltextzugriff (PDF)

1 – 25 von 134

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(131)
Mit Volltextzugriff
(119)

Publikationsform

Artikel
(133)
Buchkapitel
(1)

Sprache

Englisch
(134)

Erscheinungsjahr

n.n

Thema

Science & Technology
(88)
Life Sciences & Biomedicine
(77)
Animals
(58)
Humans
(51)
Immunology
(49)
Mice
(49)
Biological And Medical Sciences
(30)
Fundamental And Applied Biological Sciences. Psychology
(26)
T-Lymphocytes - Immunology
(23)
Fundamental Immunology
(22)
Immunobiology
(20)
Transfection
(20)
Antigens, Cd - Genetics
(19)
Base Sequence
(17)
Male
(15)
Antigens, Differentiation, T-Lymphocyte - Genetics
(14)
Female
(14)
Genes
(14)
Lymphoid Cells: Ontogeny, Maturation, Markers, Receptors, Circulation And Recirculation
(14)
Molecular Sequence Data
(14)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial

Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses

Baseline type 2 biomarker levels and response to tezepelumab in severe asthma

CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma

Tezepelumab in Adults with Uncontrolled Asthma

Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial

Immune Complex Formation Is Associated With Loss of Tolerance and an Antibody Response to Both Drug and Target

Pharmacokinetics, Safety, and Tolerability of Tezepelumab (AMG 157) in Healthy and Atopic Dermatitis Adult Subjects

Safety and Biological Activity of Rozibafusp alfa, a Bispecific Inhibitor of Inducible Costimulator Ligand and B Cell Activating Factor, in Patients With Rheumatoid Arthritis: Results of a Phase 1b, Randomized, Double‐Blind, Placebo‐Controlled, Multiple Ascending Dose Study

Efficacy of Tezepelumab in Severe, Uncontrolled Asthma: Pooled Analysis of the PATHWAY and NAVIGATOR Clinical Trials

Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY

Targeting TSLP in Asthma

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Properties of Rozibafusp Alfa, a Bispecific Inhibitor of BAFF and ICOSL: Analyses of Phase I Clinical Trials

Pharmacokinetic and Pharmacodynamic Modeling of Tezepelumab to Guide Phase 3 Dose Selection for Patients With Severe Asthma

Tezepelumab normalizes serum interleukin-5 and -13 levels in patients with severe, uncontrolled asthma

Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma with and without Nasal Polyposis: A Post Hoc Analysis of the Phase 2b PATHWAY Study

Reply to Lipworth and Chan

Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma and Perennial Allergy

Requirement for CD100–CD72 interactions in fine-tuning of B-cell antigen receptor signaling and homeostatic maintenance of the B-cell compartment

Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study

Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study

A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings

CD72 Down-Modulates BCR-Induced Signal Transduction and Diminishes Survival in Primary Mature B Lymphocytes

Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study

Long-term engagement of CD6 and ALCAM is essential for T-cell proliferation induced by dendritic cells

Suchergebnisse filtern